View ValuationEL.En 향후 성장Future 기준 점검 1/6EL.En (는) 각각 연간 12% 및 5.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.6% 로 예상됩니다.핵심 정보12.0%이익 성장률8.01%EPS 성장률Medical Equipment 이익 성장12.3%매출 성장률5.7%향후 자기자본이익률14.61%애널리스트 커버리지Low마지막 업데이트09 Jun 2026최근 향후 성장 업데이트공고 • Mar 17El.En. S.P.A. Provides Earnings Guidance for the Year 2021EL.En. S.p.A. provided earnings guidance for the year 2021. For the year, guidance for year 2021 provides for the resumption of the growth path that the pandemic has slowed down without interrupting it. Strong of its operating structures consolidated over time in an organization aimed at the medium-term sustainability of the group's success, the Company expects growth of more than 10% for 2021, with an improvement in the operating result and hopefully also in operating profitability.모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • May 21Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 1.5% to €14.56. The fair value is estimated to be €11.81, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 22% in the next 2 years.Reported Earnings • May 20First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €146.4m (up 3.9% from 1Q 2025). Net income: €20.0m (up 23% from 1Q 2025). Profit margin: 14% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.Upcoming Dividend • May 20Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 25 May 2026. Payment date: 27 May 2026. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (2.8%).Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Giovanna D'Esposito was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Mar 18EL.En. S.p.A. announces Annual dividend, payable on May 27, 2026EL.En. S.p.A. announced Annual dividend of EUR 0.2500 per share payable on May 27, 2026, ex-date on May 25, 2026 and record date on May 26, 2026.공고 • Mar 21EL.En. S.p.A., Annual General Meeting, Apr 29, 2025EL.En. S.p.A., Annual General Meeting, Apr 29, 2025, at 10:00 W. Europe Standard Time.공고 • Mar 18EL.En. S.p.A. announces Annual dividend, payable on May 21, 2025EL.En. S.p.A. announced Annual dividend of EUR 0.2200 per share payable on May 21, 2025, ex-date on May 19, 2025 and record date on May 20, 2025.Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €154.7m (up 4.2% from 3Q 2023). Net income: €15.3m (up 18% from 3Q 2023). Profit margin: 9.9% (up from 8.8% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.공고 • Nov 15+ 3 more updatesEL.En. S.p.A. to Report Q1, 2025 Results on May 15, 2025EL.En. S.p.A. announced that they will report Q1, 2025 results on May 15, 2025Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €11.64, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.73 per share.Reported Earnings • Sep 13Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €169.3m (down 8.1% from 2Q 2023). Net income: €12.9m (up 41% from 2Q 2023). Profit margin: 7.6% (up from 5.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany.Buy Or Sell Opportunity • Sep 02Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 5.8% to €10.39. The fair value is estimated to be €8.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.Buy Or Sell Opportunity • Aug 17Now 21% overvaluedOver the last 90 days, the stock has fallen 5.3% to €9.50. The fair value is estimated to be €7.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.49, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 2.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.76 per share.Reported Earnings • May 17First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.18. Revenue: €153.1m (down 5.1% from 1Q 2023). Net income: €14.4m (down 13% from 1Q 2023). Profit margin: 9.4% (in line with 1Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany.Upcoming Dividend • May 13Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 20 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (1.8%).Declared Dividend • Mar 25Dividend of €0.20 announcedShareholders will receive a dividend of €0.20. Ex-date: 20th May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (33% earnings payout ratio) but not covered by cash flows (131% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 26%After last week's 26% share price gain to €10.43, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.57 per share.Reported Earnings • Mar 16Full year 2023 earnings releasedFull year 2023 results: Revenue: €699.6m (up 3.9% from FY 2022). Net income: €48.2m (down 13% from FY 2022). Profit margin: 6.9% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Nov 15+ 4 more updatesEL.En. S.p.A. to Report Q3, 2024 Results on Nov 14, 2024EL.En. S.p.A. announced that they will report Q3, 2024 results on Nov 14, 2024Recent Insider Transactions • Oct 19Non-Executive Director recently bought €113k worth of stockOn the 10th of October, Alberto Pecci bought around 13k shares on-market at roughly €8.46 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €261k. Insiders have collectively bought €515k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Oct 08Non-Executive Director recently bought €261k worth of stockOn the 4th of October, Alberto Pecci bought around 31k shares on-market at roughly €8.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €358k more in shares than they have sold in the last 12 months.Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €184.3m (flat on 2Q 2022). Net income: €9.17m (down 16% from 2Q 2022). Profit margin: 5.0% (down from 6.0% in 2Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 22Upcoming dividend of €0.22 per share at 1.9% yieldEligible shareholders must have bought the stock before 29 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €12.44, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.11 per share.Reported Earnings • Mar 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €673.6m (up 18% from FY 2021). Net income: €55.1m (up 21% from FY 2021). Profit margin: 8.2% (up from 8.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Independent Board Member Fabia Romagnoli was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Nov 16EL.En. S.p.A., Annual General Meeting, Dec 15, 2022EL.En. S.p.A., Annual General Meeting, Dec 15, 2022, at 10:00 Central European Standard Time. Location: the registered office in Calenzano, Via Baldanzese n. 17 Calenzano Italy Agenda: To report on the 2021-2023 remuneration policy: amendment of the first section of the Report pursuant to art. 123-ter paragraph 3-bis of Legislative Decree 58/1998; to consider the approval pursuant to art. 114-bis of Legislative Decree 58/1998 of the 2026-2031 stock option plan reserved for members of the board of directors, collaborators and employees of the company and its subsidiaries; and to discuss other related matters.공고 • Nov 15+ 3 more updatesEL.En. S.p.A. to Report Fiscal Year 2022 Results on Mar 15, 2023EL.En. S.p.A. announced that they will report fiscal year 2022 results on Mar 15, 2023Reported Earnings • Sep 14Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €185.6m (up 18% from 2Q 2021). Net income: €10.9m (up 30% from 2Q 2021). Profit margin: 5.9% (up from 5.3% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany.Upcoming Dividend • May 16Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.2%).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Independent Board Member Fabia Romagnoli was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Apr 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 3.9%. The fair value is estimated to be €18.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings is also forecast to grow by 9.6% per annum over the same time period.Reported Earnings • Mar 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €577.4m (up 42% from FY 2020). Net income: €45.4m (up 124% from FY 2020). Profit margin: 7.9% (up from 5.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 9.3%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Buying Opportunity • Mar 04Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €16.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.Buying Opportunity • Feb 15Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €15.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.Buying Opportunity • Jan 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be €16.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS €0.17The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €133.1m (up 26% from 3Q 2020). Net income: €13.7m (up 73% from 3Q 2020). Profit margin: 10% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 16Investor sentiment improved over the past weekAfter last week's 16% share price gain to €16.60, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 42x in the Medical Equipment industry in Germany. Total returns to shareholders of 276% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.77 per share.Reported Earnings • Sep 15Second quarter 2021 earnings released: EPS €0.10 (vs €0.022 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €157.5m (up 75% from 2Q 2020). Net income: €8.35m (up 394% from 2Q 2020). Profit margin: 5.3% (up from 1.9% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to €15.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 182% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.42 per share.Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorated over the past weekAfter last week's 72% share price decline to €12.15, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total loss to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.57 per share.Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to €40.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 98% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €39.45 per share.Upcoming Dividend • May 17Upcoming dividend of €0.40 per shareEligible shareholders must have bought the stock before 24 May 2021. Payment date: 26 May 2021. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.3%). In line with average of industry peers (1.1%).Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 23% share price gain to €35.95, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 50x in the Medical Equipment industry in Germany. Total returns to shareholders of 162% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.22 per share.Reported Earnings • Mar 17Full year 2020 earnings releasedThe company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €413.8m (up 3.0% from FY 2019). Net income: €20.3m (down 22% from FY 2019). Profit margin: 4.9% (down from 6.5% in FY 2019). The decrease in margin was driven by higher expenses.공고 • Mar 17El.En. S.P.A. Provides Earnings Guidance for the Year 2021EL.En. S.p.A. provided earnings guidance for the year 2021. For the year, guidance for year 2021 provides for the resumption of the growth path that the pandemic has slowed down without interrupting it. Strong of its operating structures consolidated over time in an organization aimed at the medium-term sustainability of the group's success, the Company expects growth of more than 10% for 2021, with an improvement in the operating result and hopefully also in operating profitability.공고 • Mar 16EL.En. S.p.A. Proposes to Distribute a Dividend, Payable on May 26, 2021EL.En. S.p.A. resolved to propose to distribute a dividend of EUR 0.40 per share, in compliance with art. 2357-ter c.c., to be paid on May 26, 2021, to be assigned on May 24, 2021 (coupon no. 5) with record date May 25, 2021.Is New 90 Day High Low • Feb 10New 90-day high: €28.90The company is up 30% from its price of €22.20 on 11 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.84 per share.Is New 90 Day High Low • Jan 22New 90-day high: €28.75The company is up 31% from its price of €21.90 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.85 per share.Is New 90 Day High Low • Jan 06New 90-day high: €27.00The company is up 26% from its price of €21.50 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.05 per share.Is New 90 Day High Low • Dec 10New 90-day high: €26.65The company is up 20% from its price of €22.15 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €32.18 per share.Is New 90 Day High Low • Nov 19New 90-day high: €24.00The company is up 7.0% from its price of €22.35 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.17 per share.공고 • Nov 14+ 3 more updatesEL.En. S.p.A. to Report Q1, 2021 Results on May 14, 2021EL.En. S.p.A. announced that they will report Q1, 2021 results on May 14, 2021Valuation Update With 7 Day Price Move • Nov 07Market bids up stock over the past weekAfter last week's 24% share price gain to €21.80, the stock is trading at a trailing P/E ratio of 18.7x, up from the previous P/E ratio of 15.1x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total return to shareholders over the past year is a loss of 18%.Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 18% share price decline to €18.10, the stock is trading at a trailing P/E ratio of 16.1x, down from the previous P/E ratio of 19.7x. This compares to an average P/E of 53x in the Medical Equipment industry in Germany. Total return to shareholders over the past year is a loss of 27%.Is New 90 Day High Low • Oct 29New 90-day low: €18.10The company is down 19% from its price of €22.35 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.31 per share.이익 및 매출 성장 예측DB:EE5 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20287077361N/A412/31/20276656852N/A412/31/20266246058N/A43/31/202659654N/AN/AN/A12/31/2025591505971N/A9/30/202558053N/AN/AN/A6/30/2025579516068N/A3/31/202557762N/AN/AN/A12/31/2024566627483N/A9/30/202449564N/AN/AN/A6/30/2024506586272N/A3/31/202454453N/AN/AN/A12/31/202357653-112N/A9/30/202368248N/AN/AN/A6/30/202369265-128N/A3/31/202369154N/AN/AN/A12/31/202267455-162N/A9/30/202265058N/AN/AN/A6/30/202262451-126N/A3/31/202259949N/AN/AN/A12/31/2021571456379N/A9/30/202154549N/AN/AN/A6/30/2021519366679N/A3/31/202145230N/AN/AN/A12/31/2020408202839N/A9/30/202038715N/AN/AN/A6/30/202037522-212N/A3/31/202039124N/AN/AN/A12/31/201940126N/A38N/A9/30/201937732N/AN/AN/A6/30/201937720N/A29N/A3/31/201936419N/AN/AN/A12/31/201835017N/A12N/A6/30/201832717N/A21N/A3/31/201830717N/AN/AN/A12/31/201730916N/A17N/A6/30/201727716N/A14N/A3/31/201726628N/A22N/A12/31/201625540N/A30N/A6/30/201623337N/A22N/A3/31/201622626N/A15N/A12/31/201521914N/A8N/A9/30/201521415N/A10N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: EE5 의 연간 예상 수익 증가율(12%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: EE5 의 연간 수익(12%)이 German 시장(15.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: EE5 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: EE5 의 수익(연간 5.7%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: EE5 의 수익(연간 5.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: EE5의 자본 수익률은 3년 후 14.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/31 10:06종가2026/07/31 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스EL.En. S.p.A.는 6명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrea BonfaBanca Akros S.p.A. (ESN)Gustav FrobergBerenbergGiovanni SelvettiBerenberg3명의 분석가 더 보기
공고 • Mar 17El.En. S.P.A. Provides Earnings Guidance for the Year 2021EL.En. S.p.A. provided earnings guidance for the year 2021. For the year, guidance for year 2021 provides for the resumption of the growth path that the pandemic has slowed down without interrupting it. Strong of its operating structures consolidated over time in an organization aimed at the medium-term sustainability of the group's success, the Company expects growth of more than 10% for 2021, with an improvement in the operating result and hopefully also in operating profitability.
Buy Or Sell Opportunity • May 21Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 1.5% to €14.56. The fair value is estimated to be €11.81, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 22% in the next 2 years.
Reported Earnings • May 20First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €146.4m (up 3.9% from 1Q 2025). Net income: €20.0m (up 23% from 1Q 2025). Profit margin: 14% (up from 12% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.
Upcoming Dividend • May 20Upcoming dividend of €0.25 per shareEligible shareholders must have bought the stock before 25 May 2026. Payment date: 27 May 2026. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (2.8%).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Giovanna D'Esposito was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Mar 18EL.En. S.p.A. announces Annual dividend, payable on May 27, 2026EL.En. S.p.A. announced Annual dividend of EUR 0.2500 per share payable on May 27, 2026, ex-date on May 25, 2026 and record date on May 26, 2026.
공고 • Mar 21EL.En. S.p.A., Annual General Meeting, Apr 29, 2025EL.En. S.p.A., Annual General Meeting, Apr 29, 2025, at 10:00 W. Europe Standard Time.
공고 • Mar 18EL.En. S.p.A. announces Annual dividend, payable on May 21, 2025EL.En. S.p.A. announced Annual dividend of EUR 0.2200 per share payable on May 21, 2025, ex-date on May 19, 2025 and record date on May 20, 2025.
Reported Earnings • Nov 17Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: €154.7m (up 4.2% from 3Q 2023). Net income: €15.3m (up 18% from 3Q 2023). Profit margin: 9.9% (up from 8.8% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.
공고 • Nov 15+ 3 more updatesEL.En. S.p.A. to Report Q1, 2025 Results on May 15, 2025EL.En. S.p.A. announced that they will report Q1, 2025 results on May 15, 2025
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €11.64, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.73 per share.
Reported Earnings • Sep 13Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €169.3m (down 8.1% from 2Q 2023). Net income: €12.9m (up 41% from 2Q 2023). Profit margin: 7.6% (up from 5.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany.
Buy Or Sell Opportunity • Sep 02Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 5.8% to €10.39. The fair value is estimated to be €8.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.
Buy Or Sell Opportunity • Aug 17Now 21% overvaluedOver the last 90 days, the stock has fallen 5.3% to €9.50. The fair value is estimated to be €7.85, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.
Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.49, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total loss to shareholders of 2.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.76 per share.
Reported Earnings • May 17First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.18. Revenue: €153.1m (down 5.1% from 1Q 2023). Net income: €14.4m (down 13% from 1Q 2023). Profit margin: 9.4% (in line with 1Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany.
Upcoming Dividend • May 13Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 20 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 33% but the company is not cash flow positive. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (1.8%).
Declared Dividend • Mar 25Dividend of €0.20 announcedShareholders will receive a dividend of €0.20. Ex-date: 20th May 2024 Payment date: 22nd May 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (33% earnings payout ratio) but not covered by cash flows (131% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 33% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Valuation Update With 7 Day Price Move • Mar 21Investor sentiment improves as stock rises 26%After last week's 26% share price gain to €10.43, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.57 per share.
Reported Earnings • Mar 16Full year 2023 earnings releasedFull year 2023 results: Revenue: €699.6m (up 3.9% from FY 2022). Net income: €48.2m (down 13% from FY 2022). Profit margin: 6.9% (down from 8.2% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Nov 15+ 4 more updatesEL.En. S.p.A. to Report Q3, 2024 Results on Nov 14, 2024EL.En. S.p.A. announced that they will report Q3, 2024 results on Nov 14, 2024
Recent Insider Transactions • Oct 19Non-Executive Director recently bought €113k worth of stockOn the 10th of October, Alberto Pecci bought around 13k shares on-market at roughly €8.46 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €261k. Insiders have collectively bought €515k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Oct 08Non-Executive Director recently bought €261k worth of stockOn the 4th of October, Alberto Pecci bought around 31k shares on-market at roughly €8.49 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €358k more in shares than they have sold in the last 12 months.
Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €184.3m (flat on 2Q 2022). Net income: €9.17m (down 16% from 2Q 2022). Profit margin: 5.0% (down from 6.0% in 2Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 22Upcoming dividend of €0.22 per share at 1.9% yieldEligible shareholders must have bought the stock before 29 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €12.44, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 244% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.11 per share.
Reported Earnings • Mar 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €673.6m (up 18% from FY 2021). Net income: €55.1m (up 21% from FY 2021). Profit margin: 8.2% (up from 8.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Independent Board Member Fabia Romagnoli was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Nov 16EL.En. S.p.A., Annual General Meeting, Dec 15, 2022EL.En. S.p.A., Annual General Meeting, Dec 15, 2022, at 10:00 Central European Standard Time. Location: the registered office in Calenzano, Via Baldanzese n. 17 Calenzano Italy Agenda: To report on the 2021-2023 remuneration policy: amendment of the first section of the Report pursuant to art. 123-ter paragraph 3-bis of Legislative Decree 58/1998; to consider the approval pursuant to art. 114-bis of Legislative Decree 58/1998 of the 2026-2031 stock option plan reserved for members of the board of directors, collaborators and employees of the company and its subsidiaries; and to discuss other related matters.
공고 • Nov 15+ 3 more updatesEL.En. S.p.A. to Report Fiscal Year 2022 Results on Mar 15, 2023EL.En. S.p.A. announced that they will report fiscal year 2022 results on Mar 15, 2023
Reported Earnings • Sep 14Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €185.6m (up 18% from 2Q 2021). Net income: €10.9m (up 30% from 2Q 2021). Profit margin: 5.9% (up from 5.3% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Germany.
Upcoming Dividend • May 16Upcoming dividend of €0.20 per shareEligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.2%).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 6 highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Independent Board Member Fabia Romagnoli was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Apr 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 3.9%. The fair value is estimated to be €18.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.6% per annum. Earnings is also forecast to grow by 9.6% per annum over the same time period.
Reported Earnings • Mar 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €577.4m (up 42% from FY 2020). Net income: €45.4m (up 124% from FY 2020). Profit margin: 7.9% (up from 5.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 9.3%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Buying Opportunity • Mar 04Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €16.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.
Buying Opportunity • Feb 15Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €15.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.
Buying Opportunity • Jan 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be €16.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% per annum over the last 3 years. Earnings per share has grown by 32% per annum over the last 3 years.
Reported Earnings • Nov 15Third quarter 2021 earnings released: EPS €0.17The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €133.1m (up 26% from 3Q 2020). Net income: €13.7m (up 73% from 3Q 2020). Profit margin: 10% (up from 7.5% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 16Investor sentiment improved over the past weekAfter last week's 16% share price gain to €16.60, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 42x in the Medical Equipment industry in Germany. Total returns to shareholders of 276% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.77 per share.
Reported Earnings • Sep 15Second quarter 2021 earnings released: EPS €0.10 (vs €0.022 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €157.5m (up 75% from 2Q 2020). Net income: €8.35m (up 394% from 2Q 2020). Profit margin: 5.3% (up from 1.9% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to €15.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total returns to shareholders of 182% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.42 per share.
Valuation Update With 7 Day Price Move • Aug 03Investor sentiment deteriorated over the past weekAfter last week's 72% share price decline to €12.15, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 47x in the Medical Equipment industry in Germany. Total loss to shareholders of 56% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.57 per share.
Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to €40.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 48x in the Medical Equipment industry in Germany. Total returns to shareholders of 98% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €39.45 per share.
Upcoming Dividend • May 17Upcoming dividend of €0.40 per shareEligible shareholders must have bought the stock before 24 May 2021. Payment date: 26 May 2021. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.3%). In line with average of industry peers (1.1%).
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 23% share price gain to €35.95, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 50x in the Medical Equipment industry in Germany. Total returns to shareholders of 162% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €29.22 per share.
Reported Earnings • Mar 17Full year 2020 earnings releasedThe company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €413.8m (up 3.0% from FY 2019). Net income: €20.3m (down 22% from FY 2019). Profit margin: 4.9% (down from 6.5% in FY 2019). The decrease in margin was driven by higher expenses.
공고 • Mar 17El.En. S.P.A. Provides Earnings Guidance for the Year 2021EL.En. S.p.A. provided earnings guidance for the year 2021. For the year, guidance for year 2021 provides for the resumption of the growth path that the pandemic has slowed down without interrupting it. Strong of its operating structures consolidated over time in an organization aimed at the medium-term sustainability of the group's success, the Company expects growth of more than 10% for 2021, with an improvement in the operating result and hopefully also in operating profitability.
공고 • Mar 16EL.En. S.p.A. Proposes to Distribute a Dividend, Payable on May 26, 2021EL.En. S.p.A. resolved to propose to distribute a dividend of EUR 0.40 per share, in compliance with art. 2357-ter c.c., to be paid on May 26, 2021, to be assigned on May 24, 2021 (coupon no. 5) with record date May 25, 2021.
Is New 90 Day High Low • Feb 10New 90-day high: €28.90The company is up 30% from its price of €22.20 on 11 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.84 per share.
Is New 90 Day High Low • Jan 22New 90-day high: €28.75The company is up 31% from its price of €21.90 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.85 per share.
Is New 90 Day High Low • Jan 06New 90-day high: €27.00The company is up 26% from its price of €21.50 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.05 per share.
Is New 90 Day High Low • Dec 10New 90-day high: €26.65The company is up 20% from its price of €22.15 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €32.18 per share.
Is New 90 Day High Low • Nov 19New 90-day high: €24.00The company is up 7.0% from its price of €22.35 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.17 per share.
공고 • Nov 14+ 3 more updatesEL.En. S.p.A. to Report Q1, 2021 Results on May 14, 2021EL.En. S.p.A. announced that they will report Q1, 2021 results on May 14, 2021
Valuation Update With 7 Day Price Move • Nov 07Market bids up stock over the past weekAfter last week's 24% share price gain to €21.80, the stock is trading at a trailing P/E ratio of 18.7x, up from the previous P/E ratio of 15.1x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total return to shareholders over the past year is a loss of 18%.
Valuation Update With 7 Day Price Move • Oct 29Market pulls back on stock over the past weekAfter last week's 18% share price decline to €18.10, the stock is trading at a trailing P/E ratio of 16.1x, down from the previous P/E ratio of 19.7x. This compares to an average P/E of 53x in the Medical Equipment industry in Germany. Total return to shareholders over the past year is a loss of 27%.
Is New 90 Day High Low • Oct 29New 90-day low: €18.10The company is down 19% from its price of €22.35 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.31 per share.